Invesco Ltd. Purchases 902,226 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Invesco Ltd. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 53.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,590,260 shares of the medical research company’s stock after buying an additional 902,226 shares during the period. Invesco Ltd.’s holdings in IQVIA were worth $509,012,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after acquiring an additional 77,981 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after acquiring an additional 59,426 shares during the last quarter. Cantillon Capital Management LLC lifted its stake in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after purchasing an additional 226,017 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

NYSE:IQV opened at $143.98 on Wednesday. The firm has a market cap of $25.38 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 1.99 and a beta of 1.46. The firm’s fifty day moving average is $186.31 and its two-hundred day moving average is $201.80. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $138.87 and a one year high of $252.88.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Barclays dropped their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Finally, Truist Financial reiterated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.